Serialisation
Product Description
Recipharm AB
-
SE -
2015On CPHI since
-
5000+Employees
Company types
Categories
Recipharm AB
-
SE
-
2015On CPHI since
-
5000+Employees
Company types
More Products from Recipharm AB (4)
-
Product Drug Product
At Recipharm, we offer drug product development services for all common dosage forms. Our team can manage the complexity of your project, helping you find the best solution whether you are looking for development support to take your product to first-in-human (FIH) studies or to advance your product to mar... -
Product Drug Substance
Recipharm has more than 25 years’ experience in drug substance development and manufacturing. We are ideally placed to deliver a wide range of drug substance services from our dedicated development facilities around the world. -
Product Clinical Supply
Recipharm have more than 20 years experience supplying clinical trial material to our clients. Our development facilities cater for a range of clinical trials from preclincal to smaller Phase III trials. We also offer commercial manufacturing for very large clinical batches. -
Product APIs
Recipharm operate facilities which can manufacture several products at a time, handling high pressure, high temperature (up to 150 degrees Celsius) and low temperature (down to –80 degrees Celsius) reactions. Different batch sizes are available ranging from 20L to 6000L, supporting early development and co...
Recipharm AB resources (12)
-
News Sustainability in pharmaceutical manufacturing: an expert panel discussion
In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. -
Brochure Recipharm's full service offering
Your innovative drug. Our world-class production facilities. Discover the genius of working together. -
News Recipharm receives approval for the manufacture of a new microbiome-based therapeutic
Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics. -
News Watch now: Pharma Trends 2022 Webinar
We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event. -
News Lyophilisation technology improving thermal stability and reducing cycle times, says Recipharm expert
Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.
-
Sponsored Content Key considerations to develop effective analytical methods for your drug project
A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects. -
News CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task. -
News Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. -
Sponsored Content CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples. -
Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update. -
News Recipharm expands its analytical services offering in India
The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions -
News Second Curaleaf GMP cannabis facility gains Spanish approval
Medalchemy facility now fully licensed to import, cultivate, extract, manufacture and export medical cannabis flower and extracts
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance